Anavo Therapeutics

About Anavo Therapeutics

Anavo Therapeutics is a biopharmaceutical company focused on phosphatase-based drug discovery using its proprietary IGNITE platform. The company aims to unlock the therapeutic potential of phosphatase-targeted allosteric modulators, addressing previously undruggable targets. Anavo is developing first-in-class therapeutic programs and supports partners in building pipelines across various therapeutic indications.

Products & Services

IGNITE Platform:A unique drug discovery platform targeting phosphatases with allosteric strategies to address a variety of target class members across multiple indications.

Therapeutic Programs:Proprietary portfolio of programs targeting autoimmune diseases and cancer through phosphatase modulation.

Specialties

Phosphatase-based drug discovery Allosteric modulators Autoimmune disease therapeutics Cancer therapeutics

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Seed T: - FT: Seed	A: 30772000 MR: - FA: EUR 28 million FAN: 30772000	D: 2023-05-02 FD: 2023-05-02	5 investors

Seed Latest

2023-05-02

$30.8M

5 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

B

Birgit Zech

CEO

LinkedIn (Pro only)

E

Edward Holson

Chief Scientific Officer

LinkedIn (Pro only)

A

Anna Quattropani

SVP Chemistry & Non-Clinical Development

LinkedIn (Pro only)

C

Claus Schalper

FINANCIAL ADVISOR

J

Joe Lewis

Senior Vice President of Biology and Site Head Heidelberg

J

Jukka Westermarck

Professor of Cancer Biology and Research Director

View 18 more team members with Pro

Unlock Full Team Directory

Recent News